SEC Form 4 · accession 0001179110-16-022026
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Schoeneck
Officer — President and CEO · Director
Period of report
Mar 18, 2016
Accepted (ET)
Mar 21, 2016 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 18, 2016 | M | 25,000 | $3.38 | A | 31,365 | D | |
| Common StockF1 | Mar 18, 2016 | M | 2,312 | $6.11 | A | 33,677 | D | |
| Common StockF1 | Mar 18, 2016 | M | 3,171 | $6.77 | A | 36,848 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $3.38 | Mar 18, 2016 | M | 25,000 | A | — | Dec 10, 2017 | Common Stock | 25,000 | 0 | D |
| Stock OptionsF3 | $6.11 | Mar 18, 2016 | M | 2,312 | A | — | Jan 12, 2022 | Common Stock | 2,312 | 0 | D |
| Stock OptionsF4 | $6.77 | Mar 18, 2016 | M | 3,171 | A | — | Feb 7, 2023 | Common Stock | 3,171 | 17,680 | D |
Explanation of responses
- F1Amount does not include 398,735 shares of common stock held indirectly by family trust.
- F225,000 Stock Options were granted on December 10, 2007 and were exercisable in 48 equal monthly installments. The Stock Options exercised on March 18, 2016 were Non-Qualified Stock Options (NSOs).
- F3111,000 Stock Options were granted on January 12, 2012 and were exercisable in 48 equal monthly installments. The stock options exercised on March 18, 2016 were Incentive Stock Options (ISOs).
- F4196,000 Stock Options were granted on February 7, 2013 and were exercisable in 48 equal monthly installments. The stock options exercised on March 18, 2016 were Incentive Stock Options (ISOs).